Pharmacovigilance Market by Clinical Trial Phase (Pre-Clinical, Phase I, and Phase II, Phase III, and Phase IV); By Service Provider (In-House, and Contract Outsourcing); By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining); By End-Use (Hospitals, Research Organizations, and Industrial); By Geography (North America, Asia-Pacific, Europe, South America, and RoW), Industry Trends, Estimation & Forecast, 2018 – 2026

Check Today's Best Price

$3500 Buy Now
The Global Pharmacovigilance market is estimated to reach $13.05 billion by 2026, with a projected CAGR of 11.2% during the forecast period.
  • Market Overview

    The Global Pharmacovigilance market is estimated to reach $13.05 billion by 2026, with a projected CAGR of 11.2% during the forecast period. Pharmacovigilance, also known as drug safety, is the pharmacological science relating to the collection, detection, monitoring, assessment, and prevention of harmful effects with pharmaceutical products.

    Market Dynamics

    Increasing acceptance and adoption of outsourcing services by healthcare companies, and growing prevalence of adverse reactions caused by drugs are the major factors driving the growth of the global pharmacovigilance market. Moreover, government regulatory bodies such as FDA (US), and EMEA (Europe) have formulated safety regulations for the manufacturing of safe drugs, and increasing acceptance and adoption of outsourcing services by healthcare companies is likely to gain significant impetus for the Pharmacovigilance market share in the coming years.

    Market Segmentation

    The global Pharmacovigilance market is segmented based on the clinical trial phase, service provider, methods, end-use, and geography. The clinical trial phase segment includes pre-clinical, phase I, and phase II, phase III, and phase IV. By service provider segment, the categorization is given as in-house, and contract outsourcing. Spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining are the classification of the method segment. On the basis of end-use segment, the categorization comprises hospitals, research organizations, and industrial. Furthermore, geographical coverage has been offered for each of the major regions including North America, Asia-Pacific, Europe, Row, and South America.

    Scope of the Global Pharmacovigilance Market

    By Clinical Trial Phase

    • Pre-Clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV

    By Service Provider

    • In-House
    • Contract Outsourcing

    By Method

    • Spontaneous Reporting
    • Intensified ADR Reporting
    • Targeted Spontaneous Reporting
    • Cohort Event Monitoring
    • EHR Mining

    By End-Use

    • Hospitals
    • Research Organizations
    • Others

    By Geography

    • North America
      • The U.S.
      • Canada
      • Mexico
    • Europe
      • UK
      • France
      • Germany
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Korea
      • Rest of APAC
    • South America
      • Brazil
      • Rest of South America
    • Rest of the World
      • Middle East
      • Africa
    keyboard_arrow_up
  • TABLE OF CONTENTS

    Chapter 1 Introduction
    1.1 Executive Summary
    1.2 Market Definition
    1.3 Market Scope

    Chapter 2 Research Methodology
    2.1 Primary Research
    2.2 Research Methodology
    2.3 Assumptions & Exclusions
    2.4 Secondary Data Sources

    Chapter 3 Market Overview
    3.1 Report Segmentation & Scope
    3.2 Key Market Trends
    3.2.1 Drivers
    3.2.2 Restraints
    3.2.3 Opportunities
    3.3 Porter’s Five Forces Analysis
    3.4 Market Share Analysis

    Chapter 4 Global Pharmacovigilance Market by Clinical Trial Phase: Market Size and Forecast, 2018 – 2026
    4.1 Introduction
    4.1.1 Market Size and Forecast
    4.2 Pre-Clinical
    4.2.1 Market Size and Forecast
    4.3 Phase I
    4.3.1 Market Size and Forecast
    4.4 Phase II
    4.4.1 Market Size and Forecast
    4.5 Phase III
    4.5.1 Market Size and Forecast
    4.6 Phase IV
    4.6.1 Market Size and Forecast

    Chapter 5 Global Pharmacovigilance Market by Service Provider: Market Size and Forecast, 2018 – 2026
    5.1 Introduction
    5.1.1 Market Size and Forecast
    5.2 In-House
    5.2.1 Market Size and Forecast
    5.3 Contract Outsourcing
    5.3.1 Market Size and Forecast

    Chapter 6 Global Pharmacovigilance Market by Method: Market Size and Forecast, 2018 – 2026
    6.1 Introduction
    6.1.1 Market Size and Forecast
    6.2 Spontaneous Reporting
    6.2.1 Market Size and Forecast
    6.3 Intensified ADR Reporting
    6.3.1 Market Size and Forecast
    6.4 Targeted Spontaneous Reporting
    6.4.1 Market Size and Forecast
    6.5 Cohort Event Monitoring
    6.5.1 Market Size and Forecast
    6.6 EHR Mining
    6.6.1 Market Size and Forecast

    Chapter 7 Global Pharmacovigilance Market by End-Use: Market Size and Forecast, 2018 – 2026
    7.1 Introduction
    7.1.1 Market Size and Forecast
    7.2 Hospital
    7.2.1 Market Size and Forecast
    7.3 Research Organizations
    7.3.1 Market Size and Forecast
    7.4 Industrial
    7.4.1 Market Size and Forecast

    Chapter 8 Global Pharmacovigilance Market by Geography: Market Size and Forecast, 2018 – 2026
    8.1 Introduction
    8.1.1 Market Size and Forecast
    8.2 North America
    8.2.1 North America Market Size & Forecast, By Country
    8.2.2 North America Market Size & Forecast, By Clinical Trial Phase
    8.2.3 North America Market Size & Forecast, By Service Provider
    8.2.4 North America Market Size & Forecast, By Method
    8.2.5 North America Market Size & Forecast, By End-Use
    8.2.6 The U.S.
    8.2.6.1 Market Size and Forecast
    8.2.7 Canada
    8.2.7.1 Market Size and Forecast
    8.2.8 Mexico
    8.2.8.1 Market Size and Forecast
    8.3 Europe
    8.3.1 Europe Market Size and Forecast, By Country
    8.3.2 Europe Market Size and Forecast, By Clinical Trial Phase
    8.3.3 Europe Market Size and Forecast, By Service Provider
    8.3.4 Europe Market Size and Forecast, By Method
    8.3.5 Europe Market Size & Forecast, By End-Use
    8.3.6 UK
    8.3.6.1 Market Size and Forecast
    8.3.7 Germany
    8.3.7.1 Market Size and Forecast
    8.3.8 France
    8.3.8.1 Market Size and Forecast
    8.3.9 Italy
    8.3.9.1 Market Size and Forecast
    8.3.10 Spain
    8.3.10.1 Market Size and Forecast
    8.3.11 Rest of Europe
    8.3.11.1 Market Size and Forecast
    8.4 Asia-Pacific
    8.4.1 Asia-Pacific Market Size and Forecast, By Country
    8.4.2 Asia-Pacific Market Size and Forecast, By Clinical Trial Phase
    8.4.3 Asia-Pacific Market Size and Forecast, By Service Provider
    8.4.4 Asia-Pacific Market Size and Forecast, By Method
    8.4.5 Asia-Pacific Market Size and Forecast, By End-Use
    8.4.6 India
    8.4.6.1 Market Size and Forecast
    8.4.7 China
    8.4.7.1 Market Size and Forecast
    8.4.8 Australia
    8.4.8.1 Market Size and Forecast
    8.4.9 Japan
    8.4.9.1 Market Size and Forecast
    8.4.10 South Korea
    8.4.10.1 Market Size and Forecast
    8.4.11 Rest of Asia-Pacific
    8.4.11.1 Market Size and Forecast
    8.5 South America
    8.5.1 South America Market Size and Forecast, By Country
    8.5.2 South America Market Size and Forecast, By Clinical Trial Phase
    8.5.3 South America Market Size and Forecast, By Service Provider
    8.5.4 South America Market Size and Forecast, By Method
    8.5.5 South America Market Size and Forecast, By End-Use
    8.5.6 Brazil
    8.5.6.1 Market Size and Forecast
    8.5.7 Rest of South America
    8.5.7.1 Market Size and Forecast
    8.6 RoW
    8.6.1 RoW Market Size and Forecast, By Country
    8.6.2 RoW Market Size and Forecast, By Clinical Trial Phase
    8.6.3 RoW Market Size and Forecast, By Service Provider
    8.6.4 RoW Market Size and Forecast, By Method
    8.6.5 RoW Market Size and Forecast, By End-Use
    8.6.6 Middle East
    8.6.6.1 Market Size and Forecast
    8.6.7 Africa
    8.6.7.1 Market Size and Forecast

    Chapter 9 Company Profiles
    9.1 Accenture
    9.2 Capgemini
    9.3 Cognizant
    9.4 IBM Corporation
    9.5 ICON plc
    9.6 IQVIA (Quintiles IMS)
    9.7 ITClinical
    9.8 Laboratory Corporation of America Holdings
    9.9 PAREXEL International Corporation
    9.10 TCS
    9.11 United BioSource Corporation
    9.12 Wipro Ltd.

    keyboard_arrow_up
  • Pharmacovigilance Market Key Players

    • Accenture
    • Capgemini
    • Cognizant
    • IBM Corporation
    • ICON plc
    • IQVIA (Quintiles IMS)
    • ITClinical
    • Laboratory Corporation of America Holdings
    • PAREXEL International Corporation
    • TCS
    • United BioSource Corporation
    • Wipro Ltd.
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS